River Road Asset Management LLC Decreases Position in Haemonetics Corporation $HAE

River Road Asset Management LLC trimmed its position in Haemonetics Corporation (NYSE:HAE) by 33.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,102,140 shares of the medical instruments supplier’s stock after selling 552,650 shares during the period. River Road Asset Management LLC owned about 2.37% of Haemonetics worth $88,337,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after acquiring an additional 971 shares in the last quarter. Caxton Associates LLP purchased a new stake in shares of Haemonetics during the first quarter worth approximately $216,000. United Services Automobile Association purchased a new stake in shares of Haemonetics during the first quarter worth approximately $212,000. Empowered Funds LLC raised its stake in Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 372 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Haemonetics by 6.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock valued at $9,923,000 after purchasing an additional 9,051 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $74.10 on Friday. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The company has a market cap of $3.37 billion, a price-to-earnings ratio of 36.68, a PEG ratio of 1.46 and a beta of 0.56. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The business’s 50 day moving average price is $63.61 and its 200 day moving average price is $67.10.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The company had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, research analysts predict that Haemonetics Corporation will post 5.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HAE. JPMorgan Chase & Co. lowered their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Mizuho increased their target price on shares of Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday. Citigroup raised their price target on shares of Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a research note on Thursday, May 28th. Barrington Research lowered their price target on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. Finally, Weiss Ratings cut shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and a consensus target price of $78.33.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.